

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
16 August 2001 (16.08.2001)

PCT

(10) International Publication Number
WO 01/58907 A1

(51) International Patent Classification⁷: C07D 513/04,
A61K 31/519, A61P 11/00, 17/06, 29/00

Charnwood, Bakewell Road, Loughborough, Leics. LE11 5RH (GB).

(21) International Application Number: PCT/SE01/00247

(74) Agent: GLOBAL INTELLECTUAL PROPERTY; AstraZeneca AB, S-151 85 Södertälje (SE).

(22) International Filing Date: 7 February 2001 (07.02.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0003025.4 11 February 2000 (11.02.2000) GB

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(71) Applicant (*for all designated States except US*): ASTRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE).

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): BONNERT, Roger [GB/GB]; AstraZeneca, R & D Charnwood, Bakewell Road, Loughborough, Leics. LE11 5RH (GB). CAGE, Peter [GB/GB]; AstraZeneca, R & D Charnwood, Bakewell Road, Loughborough, Leics. LE11 5RH (GB). HUNT, Fraser [GB/GB]; AstraZeneca, R & D Charnwood, Bakewell Road, Loughborough, Leics. LE11 5RH (GB). JEWELL, Robert [GB/GB]; AstraZeneca, R & D Charnwood, Bakewell Road, Loughborough, Leics. LE11 5RH (GB). WALTERS, Iain [GB/GB]; AstraZeneca, R & D

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/58907 A1

(54) Title: THIAZOLOPYRIMIDINES AND THEIR USE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

(57) Abstract: The invention provides certain thiazolopyrimidine compounds, processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy.

THIAZOLOPYRIMIDINES AND THEIR USE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

The present invention relates to certain thiazolopyrimidine compounds, processes and intermediates used in their preparation, pharmaceutical compositions containing them and
5 their use in therapy.

The compound 2,7-diamino-5-methylmercapto-thiazolo[4,5-*d*]pyrimidine is known from J. Amer. Chem. Soc., 73, 4226 – 4227 (1951).

10 Chemokines play an important role in immune and inflammatory responses in various diseases and disorders, including asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. These small secreted molecules are a growing superfamily of 8-14 kDa proteins characterised by a conserved four cysteine motif. At the present time, the chemokine superfamily comprises three
15 groups exhibiting characteristic structural motifs, the C-X-C, C-C and C-X₃-C families. The C-X-C and C-C families have sequence similarity and are distinguished from one another on the basis of a single amino acid insertion between the NH-proximal pair of cysteine residues. The C-X₃-C family is distinguished from the other two families on the basis of having a triple amino acid insertion between the NH-proximal pair of cysteine
20 residues.

The C-X-C chemokines include several potent chemoattractants and activators of neutrophils such as interleukin-8 (IL-8) and neutrophil-activating peptide 2 (NAP-2).


25 The C-C chemokines include potent chemoattractants of monocytes and lymphocytes but not neutrophils. Examples include human monocyte chemotactic proteins 1-3 (MCP-1, MCP-2 and MCP-3), RANTES (Regulated on Activation, Normal T Expressed and Secreted), eotaxin and the macrophage inflammatory proteins 1 α and 1 β (MIP-1 α and MIP-1 β).

30 The C-X₃-C chemokine (also known as fractalkine) is a potent chemoattractant and activator of microglia in the central nervous system (CNS) as well as of monocytes, T cells, NK cells and mast cells.


35 Studies have demonstrated that the actions of the chemokines are mediated by subfamilies of G protein-coupled receptors, among which are the receptors designated CCR1, CCR2,

CCR2A, CCR2B, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10 and CCR11 (for the C-C family); CXCR1, CXCR2, CXCR3, CXCR4 and CXCR5 (for the C-X-C family) and CX₃CR1 for the C-X₃-C family. These receptors represent good targets for drug development since agents which modulate these receptors would be useful in the treatment of disorders and diseases such as those mentioned above.

In accordance with the present invention, there is therefore provided compounds of formula (I) or a pharmaceutically acceptable salts or solvates thereof:



wherein R represents a hydrogen atom, or a group -NR⁴R⁵;
 R⁴ and R⁵ each independently represent a hydrogen atom, or a 4-piperidiny, C₃-C₆ cycloalkyl or C₁-C₈ alkyl group, which latter two groups may be optionally substituted by one or more substituent groups independently selected from halogen atoms and -NR⁶R⁷, -CONR⁶R⁷, -OR⁸, -COOR⁸, -NR⁹COR¹⁰, -SR¹¹, -SO₂R¹¹, -SO₂NR⁶R⁷, -NR⁹SO₂R¹⁰, morpholinyl, C₁-C₄ alkyl, C₃-C₆ cycloalkyl, tetrahydrofuranyl, aryl and heteroaryl groups, the aryl and heteroaryl groups being optionally substituted by one or more substituents independently selected from halogen atoms and cyano, nitro, -NR⁶R⁷, -CONR⁶R⁷, -OR⁸, -NR⁹COR¹⁰, -SO₂NR⁶R⁷, -NR⁹SO₂R¹⁰, C₁-C₆ alkyl and trifluoromethyl groups,
 or R⁴ and R⁵ together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring system, which ring system may be optionally substituted by one or more substituent groups independently selected from



-NR⁶R⁷, -CONR⁶R⁷, -OR⁸, -COOR⁸, -NR⁹COR¹⁰, and C₁-C₆ alkyl optionally substituted by one or more substituents independently selected from halogen atoms and -NR¹¹R¹² and -OR⁸ groups,

- R^1 represents a C_1 - C_8 alkyl group optionally containing one or more atoms independently selected from O, NR^6 or S which terminates in a heteroaryl group, the latter group may be optionally substituted by one or more substituent groups independently selected from halogen atoms, $-NR^6R^7$, $-CONR^6R^7$, $-OR^8$, $-COOR^8$, $-NR^9COR^{10}$, $-SR^{11}$, $-SO_2R^{11}$, $-SO_2NR^6R^7$, $-NR^9SO_2R^{10}$, C_1 - C_6 alkyl, trifluoromethyl, or an aryl or heteroaryl group each of which can be optionally substituted by one or more substituents independently selected from halogen atoms, cyano, nitro, $-NR^6R^7$, $-CONR^6R^7$, $-OR^8$, $-COOR^8$, $-NR^9COR^{10}$, $-SR^{11}$, $-SO_2R^{11}$, $-SO_2NR^6R^7$, $-NR^9SO_2R^{10}$, C_1 - C_6 alkyl or trifluoromethyl groups.
- R^2 and R^3 each independently represent a hydrogen atom, or a C_3 - C_7 carbocyclic, C_1 - C_8 alkyl, C_2 - C_6 alkenyl or C_2 - C_6 alkynyl group, the latter four groups may be optionally substituted by one or more substituent groups independently selected from: halogen atoms, $-NR^6R^7$, $-CONR^6R^7$, $-OR^8$, $-COOR^8$, $-NR^9COR^{10}$, $-SR^{11}$, $-SO_2R^{11}$, $-SO_2NR^6R^7$, $-NR^9SO_2R^{10}$
- or
- a 3-8 membered ring optionally containing one or more atoms selected from O, S, NR^9 and itself optionally substituted by C_{1-3} -alkyl, halogen,
- R^8 represents hydrogen, C_1 - C_6 alkyl or a phenyl group the latter two of which may be optionally substituted by one or more substituent groups independently selected from halogen atoms, phenyl, $-OR^{14}$ and $-NR^{15}R^{16}$, $-CONR^{15}R^{16}$, $-NR^{15}COR^{16}$, $-SO_2NR^{15}R^{16}$, $NR^{15}SO_2R^{16}$
- R^6 and R^7 independently represent a hydrogen atom or a C_1 - C_6 alkyl or phenyl group the latter two of which may be optionally substituted by one or more substituent groups independently selected from halogen atoms, phenyl, $-OR^{14}$ and $-NR^{15}R^{16}$, $-CONR^{15}R^{16}$, $-NR^{15}COR^{16}$, $-SO_2NR^{15}R^{16}$, $NR^{15}SO_2R^{16}$
- or
- R^6 and R^7 together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring system optionally comprising a further heteroatom selected from oxygen and nitrogen atoms, which ring system may be optionally substituted by one or more substituent groups independently selected from phenyl, $-OR^{14}$, $-COOR^{14}$, $-NR^{15}R^{16}$, $-CONR^{15}R^{16}$, $-NR^{15}COR^{16}$, $-SO_2NR^{15}R^{16}$, $NR^{15}SO_2R^{16}$ or C_1 - C_6 alkyl, itself optionally substituted by one or more substituents independently selected from halogen atoms and $-NR^{15}R^{16}$ and $-OR^{17}$ groups,

R^{11} represents a hydrogen atom or a C_1 - C_6 , or phenyl group, each of which may be optionally substituted by one or more substituent groups independently selected from halogen atoms, phenyl, $-OR^{17}$ and $-NR^{15}R^{16}$, and

- 5 R^9 , R^{10} , R^{12} , R^{13} , R^{14} , R^{15} , R^{16} , and R^{17} independently represent a hydrogen atom or a C_1 - C_6 , alkyl, or a phenyl group.

In the context of the present specification, unless otherwise indicated, an alkyl or alkenyl group or an alkyl or alkenyl moiety in a substituent group may be linear or branched.

10

Aryl groups include phenyl and naphthyl. Heteroaryl is defined as a 5- or 6-membered aromatic ring optionally containing one or more heteroatoms selected from N, S, O.

Examples include pyridine, pyrimidine, thiazole, oxazole, pyrazole, imidazole, furan.

Heterocyclic rings as defined for R^4 and R^5 means saturated heterocycles, examples of

- 15 which include morpholine, azetidine, pyrrolidine, piperidine and piperazine.

In formula (I) above, the group R represents a hydrogen atom, or a group $-NR^4R^5$.

Particularly advantageous compounds of formula (I) are those in which R represents a group $-NR^4R^5$.


20

Suitably R^4 and R^5 each independently represent a hydrogen atom, or a 4-piperidinyl, C_3 - C_6 cycloalkyl or C_1 - C_8 alkyl group, which latter two groups may be optionally substituted by one or more substituent groups independently selected from halogen atoms and $-NR^6R^7$, $-CONR^6R^7$, $-OR^8$, $-COOR^8$, $-NR^9COR^{10}$, $-SR^{11}$, $-SO_2R^{11}$, $-SO_2NR^6R^7$, $-NR^9SO_2R^{10}$,

- 25 morpholinyl, C_1 - C_4 alkyl, C_3 - C_6 cycloalkyl, tetrahydrofuranyl, aryl and heteroaryl groups, each of which may be optionally substituted by one or more substituents independently selected from halogen atoms and cyano, nitro, $-NR^6R^7$, $-CONR^6R^7$, $-OR^8$, $-NR^9COR^{10}$, $-SO_2NR^6R^7$, $-NR^9SO_2R^{10}$, C_1 - C_6 alkyl and trifluoromethyl groups,

or R^4 and R^5 together with the nitrogen atom to which they are attached form a 4- to

- 30 7-membered saturated heterocyclic ring system, which ring system may be optionally substituted by one or more substituent groups independently selected from



$-\text{NR}^6\text{R}^7$, $-\text{CONR}^6\text{R}^7$, $-\text{OR}^8$, $-\text{COOR}^8$, $-\text{NR}^9\text{COR}^{10}$, and $\text{C}_1\text{-C}_6$ alkyl optionally substituted by one or more substituents independently selected from halogen atoms and $-\text{NR}^{11}\text{R}^{12}$ and $-\text{OR}^8$ groups.

- 5 Particularly advantageous compounds of formula (I) are those in which R^4 and R^5 each represent a hydrogen atom.

Suitably R^1 represents a $\text{C}_1\text{-C}_8$ alkyl group optionally containing one or more atoms independently selected from O, NR^6 or S which terminates in a heteroaryl group, the latter
 10 group may be optionally substituted by one or more substituent groups independently selected from halogen atoms, $-\text{NR}^6\text{R}^7$, $-\text{CONR}^6\text{R}^7$, $-\text{OR}^8$, $-\text{COOR}^8$, $-\text{NR}^9\text{COR}^{10}$, $-\text{SR}^{11}$, $-\text{SO}_2\text{R}^{11}$, $-\text{SO}_2\text{NR}^6\text{R}^7$, $-\text{NR}^9\text{SO}_2\text{R}^{10}$, $\text{C}_1\text{-C}_6$ alkyl, trifluoromethyl, or an aryl or heteroaryl group each of which can be optionally substituted by one or more substituents independently selected from halogen atoms, cyano, nitro, $-\text{NR}^6\text{R}^7$, $-\text{CONR}^6\text{R}^7$, $-\text{OR}^8$,
 15 $-\text{COOR}^8$, $-\text{NR}^9\text{COR}^{10}$, $-\text{SR}^{11}$, $-\text{SO}_2\text{R}^{11}$, $-\text{SO}_2\text{NR}^6\text{R}^7$, $-\text{NR}^9\text{SO}_2\text{R}^{10}$, $\text{C}_1\text{-C}_6$ alkyl or trifluoromethyl groups.

Particularly advantageous compounds of formula (I) are those in which R^1 represents a methyl group substituted by a five-membered heterocycle such as furan or thiazole.

20

Suitably R^2 and R^3 each independently represent a hydrogen atom, or a $\text{C}_3\text{-C}_7$ carbocyclic, $\text{C}_1\text{-C}_8$ alkyl, $\text{C}_2\text{-C}_6$ alkenyl or $\text{C}_2\text{-C}_6$ alkynyl group, the latter four groups may be optionally substituted by one or more substituent groups independently selected from:

halogen atoms, $-\text{NR}^6\text{R}^7$, $-\text{CONR}^6\text{R}^7$, $-\text{OR}^8$, $-\text{COOR}^8$, $-\text{NR}^9\text{COR}^{10}$, $-\text{SR}^{11}$, $-\text{SO}_2\text{R}^{11}$, $-\text{SO}_2\text{NR}^6\text{R}^7$, $-\text{NR}^9\text{SO}_2\text{R}^{10}$

25

or

a 3-8 membered ring optionally containing one or more atoms selected from O, S, NR^9 and itself optionally substituted by C_{1-3} -alkyl, halogen.

- 30 Preferably one of R^2 and R^3 is hydrogen and the other is $\text{C}_1\text{-C}_8$ alkyl substituted by hydroxy and one or more methyl or ethyl groups. More preferably one of R^2 and R^3 is hydrogen and the other is $\text{CH}(\text{CH}_3)\text{CH}_2\text{OH}$, $\text{CH}(\text{Et})\text{CH}_2\text{OH}$, $\text{C}(\text{CH}_3)_2\text{CH}_2\text{OH}$ or $\text{CH}(\text{CH}_2\text{OH})_2$. When one of R^2 and R^3 is hydrogen and the other is $\text{CH}(\text{CH}_3)\text{CH}_2\text{OH}$ or $\text{CH}(\text{Et})\text{CH}_2\text{OH}$ the resulting compounds of formula (I) are preferably in the form of the (R)
 35 isomer. Most preferably one of R^2 and R^3 is hydrogen and the other is $\text{CH}(\text{CH}_3)\text{CH}_2\text{OH}$.

Particularly preferred compounds of the invention include:

2-[[2-Amino-5-[(1*H*-benzimidazol-2-ylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol

2-[[2-Amino-5-[(2-furanylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol

2-[[2-Amino-5-[[1-(2-thienyl)ethyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol

(2*R*)- 2-[[2-Amino-5-[(2-methyl-4-thiazolyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol

(2*R*)- 2-[[2-Amino-5-[(3,5-dimethyl-4-isoxazolyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol

(2*R*)- 2-[[2-Amino-5-[(5-methyl-2-furanyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol.

N-[4-[[[2-Amino-7-[(1*R*)-2-hydroxy-1-methylethyl]amino]thiazolo[4,5-*d*]pyrimidin-5-yl]thio]methyl]-2-thiazolyl]-acetamide,

(2*R*)-2-[[2-Amino-5-[[[(5-chloro-1,2,3-thiadiazol-4-yl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol

(2*R*)-2-[[2-Amino-5-[(5-isoxazolylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol

2-[[2-Amino-5-[[[(2-methyl-4-thiazolyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1,3-propanediol

2-[[2-Amino-5-[[[(2-methyl-4-thiazolyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol


(2*R*)-2-[[2-Amino-5-[(2-furanylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol

and their pharmaceutically acceptable salts and solvates.

According to the invention there is also provided a process for the preparation of a compound of formula (I) which comprises:

30


a) treatment of a compound of formula (II):



where R, R¹, R² and R³ are as defined in formula (I) or are protected derivatives thereof with a thiol R¹SH in the presence of a base, or

5

(b) treatment of a compound of formula (III):



10 where R, R² and R³ are as defined in formula (I) or are protected derivatives thereof with a compound of formula R¹X where R¹ is as defined in formula (I) and X is a leaving group, and optionally after (a) or (b):


- removing any protecting groups;
- forming a pharmaceutically acceptable salt or solvate.

15

Reaction (a) may be carried out in a solvent such as DMSO at a temperature between 0°C and 100°C using a base such as potassium *tert*-butoxide.

20 Reaction (b) may be carried out in NMP at room temperature. The leaving group X is preferably halogen such as bromide. Preferably the reaction is carried out in the presence of a base such as *N,N*-diisopropylethylamine. The reaction may be carried out in a suitable solvent such as NMP at room temperature.

25 Compounds of formula (II) where R¹, R² and R³ are as defined in formula (I) may be prepared by treatment of a compound of formula (IV):




where R, R¹, R² and R³ are as defined above with an oxidizing agent such as peracetic acid. The reaction may be carried out in a solvent such as glacial acetic acid at a
 5 temperature between 0°C and 100°C.

Compounds of formula (III) where R, R² and R³ are as defined in formula (I) may be prepared by treatment of a compound of formula (IV) where R, R¹, R² and R³ are as defined in formula (I) with sodium in liquid ammonia.

10

Compounds of formula (IV) where R, R¹, R² and R³ are as defined in formula (I) may be prepared by treatment of a compound of formula (V) where R and R¹ is as defined above and L is a halogen such as chlorine with an amine HNR₂R₃. The reaction may be carried out in a solvent such as tetrahydrofuran in a sealed vessel at a temperature between 0°C
 15 and 150°C.



Compounds of formula (V) where R and R¹ are as defined in formula (I) and L is a halogen
 20 may be prepared by treating a compound of formula (V) where R and R¹ are as defined in formula (I) and L is a hydroxyl group with a halogenating agent such as phosphorous oxychloride. The reaction may be carried out at reflux in the presence of dimethylaniline.


Compounds of formula (V) where R = NH₂ and R¹ is as defined in formula (I) and L is a
 25 hydroxyl group may be formed by heating a compound of formula (VI) where R¹ is as defined above.

Compounds of formula (V) where R and R¹ is defined in formula (I) and L is a halogen can be prepared from compounds of formula (V) where R is a halogen and R¹ is defined above with an amine NR⁴R⁵. The reaction may be carried out in a solvent such as tetrahydrofuran in a sealed vessel at a temperature between 0°C and 150°C.

5

Compounds of formula (V) where R is a halogen, R¹ is defined in formula (I) and L is a halogen can be prepared from compounds of formula (V) where R is NH₂ and R¹ and L are defined above with a diazotizing agent and a halogenating agent. This process is conveniently carried out in an organic solvent such as acetonitrile in the presence of a


10 diazotizing agent such as *tert*-butyl nitrite and a halogenating agent such as a trimethylsilyl halide.



15


Compounds of formula (VI) where R¹ is as defined in formula (I) may be readily prepared by reacting a compound of general formula (VII) wherein R¹ is as defined above, with potassium thiocyanate and bromine in an inert solvent such as dimethylformamide/pyridine.

20 Compounds of formula (V) where R=NH₂ and R¹ is defined in formula (I) and L is a hydroxyl group may also be prepared from compounds of general formula (VII) without isolation of intermediate (VI).



25

Compounds of formula (VII) are suitably prepared by reacting a compound of formula (VIII):



with a compound of formula R^1X where R^1 is as defined above and X is a leaving group such as bromide in the presence of a base such as sodium hydroxide.

5

It will be appreciated by those skilled in the art that in the processes of the present invention certain functional groups such as hydroxyl or amino groups in the starting reagents or intermediate compounds may need to be protected by protecting groups. Thus, the preparation of the compounds of formula (I) may involve, at an appropriate stage, the removal of one or more protecting groups. The protection and deprotection of functional groups is fully described in 'Protective Groups in Organic Chemistry', edited by J. W. F. McOmie, Plenum Press (1973), and 'Protective Groups in Organic Synthesis', 2nd edition, T. W. Greene & P. G. M. Wuts, Wiley-Interscience (1991).

15 Novel intermediate compounds form a further aspect of the invention. In particular compounds of formula (II) and (III) are novel and form an aspect of the invention.

The compounds of formula (I) above may be converted to a pharmaceutically acceptable salt or solvate thereof, preferably a basic addition salt such as sodium, potassium, calcium, aluminium, lithium, magnesium, zinc, benzathine, chlorprocaine, choline, diethanolamine, ethanolamine, ethyldiamine, meglumine, tromethamine or procaine, or an acid addition salt such as a hydrochloride, hydrobromide, phosphate, acetate, fumarate, maleate, tartrate, citrate, oxalate, methanesulphonate or *p*-toluenesulphonate.

25 The compounds of formula (I) have activity as pharmaceuticals, in particular as modulators of chemokine receptor (especially CXCR2) activity, and may be used in the treatment (therapeutic or prophylactic) of conditions/diseases in human and non-human animals which are exacerbated or caused by excessive or unregulated production of chemokines. Examples of such conditions/diseases include:

30

- (1) **(the respiratory tract)** obstructive airways diseases including chronic obstructive pulmonary disease (COPD); asthma, such as bronchial, allergic,

intrinsic, extrinsic and dust asthma, particularly chronic or inveterate asthma (e.g. late asthma and airways hyper-responsiveness); bronchitis; acute, allergic, atrophic rhinitis and chronic rhinitis including rhinitis caseosa, hypertrophic rhinitis, rhinitis purulenta, rhinitis sicca and rhinitis medicamentosa; membranous rhinitis including croupous, fibrinous and pseudomembranous rhinitis and scrofulous rhinitis; seasonal rhinitis including rhinitis nervosa (hay fever) and vasomotor rhinitis; sarcoidosis, farmer's lung and related diseases, fibroid lung and idiopathic interstitial pneumonia;

(2) **(bone and joints)** rheumatoid arthritis, seronegative spondyloarthropathies (including ankylosing spondylitis, psoriatic arthritis and Reiter's disease), Behcet's disease, Sjogren's syndrome and systemic sclerosis;

(3) **(skin)** psoriasis, atopic dermatitis, contact dermatitis and other eczematous dermatides, seborrhoetic dermatitis, Lichen planus, Pemphigus, bullous Pemphigus, Epidermolysis bullosa, urticaria, angiodermas, vasculitides, erythemas, cutaneous eosinophilias, uveitis, Alopecia areata and vernal conjunctivitis;

(4) **(gastrointestinal tract)** Coeliac disease, proctitis, eosinophilic gastro-enteritis, mastocytosis, Crohn's disease, ulcerative colitis, food-related allergies which have effects remote from the gut, e.g., migraine, rhinitis and eczema;

(5) **(central and peripheral nervous system)** Neurodegenerative diseases and dementia disorders, e.g. Alzheimer's disease, amyotrophic lateral sclerosis and other motor neuron diseases, Creutzfeldt-Jacob's disease and other prion diseases, HIV encephalopathy (AIDS dementia complex), Huntington's disease, frontotemporal dementia, Lewy body dementia and vascular dementia; polyneuropathies, e.g. Guillain-Barré syndrome, chronic inflammatory demyelinating polyradiculoneuropathy, multifocal motor neuropathy, plexopathies; CNS demyelination, e.g. multiple sclerosis, acute disseminated/haemorrhagic encephalomyelitis, and subacute sclerosing panencephalitis; neuromuscular disorders, e.g. myasthenia gravis and Lambert-

Eaton syndrome; spinal disorders, e.g. tropical spastic paraparesis, and stiff-man syndrome; paraneoplastic syndromes, e.g. cerebellar degeneration and encephalomyelitis; CNS trauma; migraine; and stroke.

- 5 (6) **(other tissues and systemic disease)** atherosclerosis, Acquired Immunodeficiency Syndrome (AIDS), lupus erythematosus, systemic lupus erythematosus, Hashimoto's thyroiditis, type I diabetes, nephrotic syndrome, eosinophilia fascitis, hyper IgE syndrome, lepromatous leprosy, and idiopathic thrombocytopenia purpura; post-operative adhesions, and sepsis.
- 10 (7) **(allograft rejection)** acute and chronic following, for example, transplantation of kidney, heart, liver, lung, bone marrow, skin and cornea; and chronic graft versus host disease;
- 15 (8) Cancers, especially non-small cell lung cancer (NSCLC), malignant melanoma, prostate cancer and squamous sarcoma, and tumour metastasis;
- (9) Diseases in which angiogenesis is associated with raised CXCR2 chemokine levels (e.g. NSCLC, diabetic retinopathy).
- 20 (10) Cystic fibrosis, re-perfusion injury in the heart, brain, peripheral limbs and other organs.
- (11) Burn wounds & chronic skin ulcers
- 25 (12) Reproductive Diseases (e.g. Disorders of ovulation, menstruation and implantation, Pre-term labour, Endometriosis)

30 Thus, the present invention provides a compound of formula (I), or a pharmaceutically-acceptable salt or solvate thereof, as hereinbefore defined for use in therapy.

 Preferably the compounds of the invention are used to treat diseases in which the chemokine receptor belongs to the CXC chemokine receptor subfamily, more preferably the target chemokine receptor is the CXCR2 receptor,

Particular conditions which can be treated with the compounds of the invention are psoriasis, diseases in which angiogenesis is associated with raised CXCR2 chemokine levels, and COPD. It is preferred that the compounds of the invention are used to treat psoriasis.

5

As a further aspect of the present invention, certain compounds of formula (I) may have utility as antagonists of the CX3CR1 receptor. Such compounds are expected to be particularly useful in the treatment of disorders within the central and peripheral nervous system and other conditions characterized by an activation of microglia and/or infiltration of leukocytes (e.g. stroke/ischemia and head trauma).

10

In a further aspect, the present invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined in the manufacture of a medicament for use in therapy.

15

In a still further aspect, the present invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined in the manufacture of a medicament for the treatment of human diseases or conditions in which modulation of chemokine receptor activity is beneficial.

20

In the context of the present specification, the term "therapy" also includes "prophylaxis" unless there are specific indications to the contrary. The terms "therapeutic" and "therapeutically" should be construed accordingly.

25

The invention still further provides a method of treating a chemokine mediated disease wherein the chemokine binds to a chemokine (especially CXCR2) receptor, which comprises administering to a patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined.

30

The invention also provides a method of treating an inflammatory disease, especially psoriasis, in a patient suffering from, or at risk of, said disease, which comprises administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined.

35

For the above-mentioned therapeutic uses the dosage administered will, of course, vary with the compound employed, the mode of administration, the treatment desired and the disorder indicated.

5 The compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof may be used on their own but will generally be administered in the form of a pharmaceutical composition in which the formula (I) compound/salt/solvate (active ingredient) is in association with a pharmaceutically acceptable adjuvant, diluent or carrier. Depending on the mode of administration, the pharmaceutical composition will preferably
10 comprise from 0.05 to 99 %w (per cent by weight), more preferably from 0.05 to 80 %w, still more preferably from 0.10 to 70 %w, and even more preferably from 0.10 to 50 %w, of active ingredient, all percentages by weight being based on total composition.

The present invention also provides a pharmaceutical composition comprising a compound
15 of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined, in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

The invention further provides a process for the preparation of a pharmaceutical composition of the invention which comprises mixing a compound of formula (I), or a
20 pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined, with a pharmaceutically acceptable adjuvant, diluent or carrier.

The pharmaceutical compositions may be administered topically (e.g. to the lung and/or airways or to the skin) in the form of solutions, suspensions, heptafluoroalkane aerosols
25 and dry powder formulations; or systemically, e.g. by oral administration in the form of tablets, capsules, syrups, powders or granules, or by parenteral administration in the form of solutions or suspensions, or by subcutaneous administration or by rectal administration in the form of suppositories or transdermally. Preferably the compounds of the invention are administered orally.

30 The invention will now be further illustrated by reference to the following examples. In the examples the Nuclear Magnetic Resonance (NMR) spectra were measured on a Varian Unity Inova 300 or 400 MHz spectrometer and the Mass Spectrometry (MS) spectra measured on a Finnigan Mat SSQ7000 or Micromass Platform spectrometer. Where
35 necessary, the reactions were performed under an inert atmosphere of either nitrogen or argon. Chromatography was generally performed using Matrex Silica 60[®] (35-70 micron)

or Prolabo Silica gel 60[®] (35-70 micron) suitable for flash silica gel chromatography. High pressure liquid chromatography purification was performed using either a Waters Micromass LCZ with a Waters 600 pump controller, Waters 2487 detector and Gilson FC024 fraction collector or a Waters Delta Prep 4000. The abbreviations m.p. and DMSO
5 used in the examples stand for melting point and dimethyl sulphoxide respectively.

Example 1

2-[[2-Amino-5-[(1*H*-benzimidazol-2-ylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-
10 yl]amino]-2-methyl-1-propanol

(a) 6-Amino-1,4-dihydro-2-[(phenylmethyl)thio]-4-oxo-5-thiocyanic acid, pyrimidinyl
ester

15 6-Amino-2-[(phenylmethyl)thio]-4(1*H*)-pyrimidinone (10.5g) [preparation as described in WO 9635678] and potassium thiocyanate (25g) in *N,N*-dimethylformamide (200ml) were heated together at 65°C. Pyridine (6.3ml) was added and the solution cooled to 5°C. Bromine (2.2ml) was added slowly and the reaction mixture stirred for 2 hours at 5-10°C. The reaction mixture was poured onto ice water, stirred for 1 hour and the solid was
20 isolated by filtration. After washing with water and ether, a pure sample was obtained after tituration with hot methanol.

MS (APCI) 291 (M+H, 100%).

25 (b) 2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one

The product of step a) (7.35g) was heated at 120°C in *N,N*-dimethylformamide (40ml)/water (10ml) for 10 hours. After cooling, the resulting solid was filtered off, washed with water, then ethyl acetate to give the subtitle compound.

30

m.p. ~325°C

MS (APCI) 291 (M+H, 100%).

(c) 7-Chloro-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-2-amine

35

The product from step (b) (0.89g), phosphorus oxychloride (12ml) and *N,N*-

dimethylaniline (1.2ml) were heated at reflux for 2 hours. The cooled reaction mixture was poured onto ice water and stirred for 2 hours. Chromatography (SiO₂, methanol/dichloromethane as eluant) gave the sub-title compound.

5 m.p. 217-218.5°C
MS (APCI) 309 (M+H, 100%).

(d) 2-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol

10

The product from step (c) (0.6g) and 2-amino-2-methylpropanol (1.1g) in tetrahydrofuran (10ml) was heated in a sealed vessel at 100 °C for 18 hours. The mixture was evaporated to dryness and purified (SiO₂, ethyl acetate as eluant) to give the subtitle compound (0.46g).

15

MS (APCI) 362 (M+H⁺, 100%).

(e) 2-[[2-Amino-5-[(phenylmethyl)sulfonyl]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol

20

A solution of the product from step (d) (0.65g) in glacial acetic acid (75ml) was treated with peracetic acid (36-40% w/w in acetic acid, 0.93ml) and stirred for 1 hour. The solution was treated with more peracetic acid (3x 2ml) over 40 minutes, and stirred at
25 70°C for 1 hour. The excess reagent was destroyed with dimethyl sulphide, and the solution was evaporated. The residue was slurried in toluene and evaporated (3x) to give the subtitled compound, contaminated with a little DMSO

MS: APCI 394 (M+H)

30

(f) 2-[[2-Amino-5-[(1*H*-benzimidazol-2-yl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol

The product from step (e) was taken up in DMSO (7.5ml) and treated with potassium *t*-butoxide (1M in THF, 4.95ml). An aliquot of the solution (1ml) was treated with (1*H*-benzimidazol-2-yl)methanethiol (0.063g) and stirred at 50°C for 1 hour. The solution was
35

treated with glacial acetic acid (1ml) and purified by reverse phase preparative HPLC on Symmetry[®] C8 column, using 10 to 60% acetonitrile in 0.1% aqueous ammonium acetate at 20ml/min over 5 min to give the titled compound (0.013g)

5 MS: APCI 402 (M+H)

¹H NMR: δ (DMSO) 1.32(s, 6H), 3.56 (d, 2H), 4.57 (s, 2H), 4.87 (t, 1H), 6.34 (s, 1H), 7.13 (m, 2H), 7.43-7.52 (m, 2H), 8.01 (s, 2H), 12.33 (s, 1H).

Example 2

10

2-[[2-Amino-5-[(2-furanylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol

15 The titled compound was prepared from furfuryl mercaptan (0.043g) using the method of example 1, step (f) (0.013g)

MS: APCI 352 (M+H)

¹H NMR: δ (DMSO) 1.33 (s, 6H), 3.55 (d, 2H), 4.38 (s, 2H), 4.87 (t, 1H), 6.30-6.38 (m, 3H), 7.56 (bs, 1H), 8.01 (s, 2H),

20

Example 3

2-[[2-Amino-5-[[1-(2-thienyl)ethyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol

25

The titled compound was prepared from 1-(2-thienyl)ethyl mercaptan (0.055g) using the method of example 1, step (f) (0.008g)

MS: APCI 382 (M+H)

30 ¹H NMR: δ (DMSO) 1.33 (s, 6H), 1.77 (s, 3H), 3.55 (d, 2H), 4.88 (t, 1H), 5.26 (q, 1H), 6.31 (s, 1H), 6.95-6.97 (m, 1H), 7.90 (d, 1H), 7.40 (dd, 1H), 8.00 (s, 2H),

Example 4

35 **(2*R*)- 2-[[2-Amino-5-[[2-methyl-4-thiazolyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol**

(a) (2R)-2-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]- 1-propanol

- 5 Prepared by the method of example 1, step (d), using the product of example 1, step (c) and (*R*)-(-)-2-amino-1-propanol.

MS (APCI) 348 (M+H⁺, 100%).

10 **(b) (2R)- 2-[(2-Amino-5-mercaptothiazolo[4,5-*d*]pyrimidin-7-yl)amino]- 1-propanol**

A stirred solution of the product of step (a) (1g) in liquid ammonia (20ml) was treated portionwise with sodium until a permanent blue colour was obtained. The solution was treated with ammonium chloride to dissipate the blue colour, and allowed to evaporate.

- 15 The residue was taken up in water, filtered and purified by reverse phase preparative HPLC on Xterra[®] C8 column, using 0 to 20% acetonitrile in water at 20ml/min over 2 min to give the subtitled compound (0.22g)

MS: APCI 258 (M+H)

- 20 ¹H NMR: δ (DMSO) 1.09 (d, 3H), 3.39-3.42 (m, obscured by DMSO), 4.05 (bs, 2H), 5.55 (b), 5.99 (b), 7.57 (bs, 2H)

(c) (2R)- 2-[[2-Amino-5-[(2-methyl-4-thiazolyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol

25

A stirred solution of the product of step (b) (0.05g) in DMSO (4ml) was treated with a solution of 4-chloromethyl-2-methylthiazole hydrochloride (0.029g) and Hunig's base (0.025g) in NMP (0.5ml) and stirred for 1 hour. The solution was purified by reverse phase preparative HPLC on Nova-pak[®] C18 column, using 10 to 60% acetonitrile in 0.1% aqueous ammonium acetate at 50ml/min over 10 min to give the titled compound (0.021g)

30

MS: APCI 369 (M+H)

¹H NMR: δ (CD₃OD) 1.21 (d, 3H), 2.68 (s, 3H), 3.48-3.64 (mult., 2H), 4.33-4.40 (mult., 1H), 4.46 (s, 2H), 7.31 (s, 1H)

35

Example 5

(2R)- 2-[[2-Amino-5-[[3,5-dimethyl-4-isoxazolyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-propanol

- 5 The titled compound was prepared from the product of example 4, step (b), and 3,5-dimethyl-4-chloromethylisoxazole using the method of example 4, step (c) to give a white powder (0.016g)

MS: APCI 367 (M+H)

10

Example 6

(2R)- 2-[[2-Amino-5-[[5-methyl-2-furanyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-propanol.

15

(a) (2R)-2-[[2-Amino-5-[(phenylmethyl)sulphonyl]thiazolo[4,5-d]pyrimidin-7-yl]amino]- 1-propanol.

- 20 The product from example 4, step (a), was converted into the subtitled compound by the method of example 1, step (e)

MS: APCI 380 (M+H)

(b) (5-Methylfuran-2-yl)methyl mercaptan

25

- A stirred solution of thiourea (0.18g) in concentrated hydrochloric acid (0.8ml) and water (1ml) was treated with 5-methylfurfuryl alcohol (0.2g) and stirred for 0.5h. The mixture was diluted with water to give a clear solution, washed with ether, basified with 10% w/v aqueous sodium hydroxide solution, stirred for 10 min, acidified with concentrated hydrochloric acid and extracted with ether. The washed and dried (MgSO₄) extracts were
30 evaporated to give the subtitled compound as a yellow oil that rapidly oxidised to its disulphide (0.05g)

¹H NMR: δ (CDCl₃) 1.88 (t, 1H), 2.28 (s, 3H), 3.71 (d, 2H), 5.86 (m, 1H), 6.03 (m, 1H).

35

(c) (2*R*)- 2-[[2-Amino-5-[[[(5-methyl-2-furanyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol.

A solution of the product from step (a) was converted into the titled compound using the
5 product from step (b), and the method of example 1, step (f)

MS: APCI 352 (M+H)

¹H NMR: δ (CD₃OD) 1.15(d, 3H), 2.13 (s, 3H), 3.42-3.57 (m, 2H), 4.26-4.31(m, 2H), 5.78
(m, 1H), 6.03 (m, 1H)

10

Example 7

N-[4-[[[2-Amino-7-[[[(1*R*)-2-hydroxy-1-methylethyl]amino]thiazolo[4,5-*d*]pyrimidin-5-yl]thio]methyl]-2-thiazolyl]-acetamide,

15

The titled compound was prepared from the product of example 4, step (b), and *N*-[4-(chloromethyl)-2-thiazolyl]-acetamide, using the method of example 4, step (c)

MS: APCI 412 (M+H)

20 ¹H NMR: δ (DMSO) 1.12 (d, 3H), 2.11 (s, 3H), 3.33-3.49 (m, 2H), 4.27 (quin, 1H), 4.40 (s, 2H), 7.01 (s, 1H), 7.58 (bs, 1H), 8.36 (bs, 2H), 12.14 (s, 1H).

Example 8

25 (2*R*)-2-[[2-Amino-5-[[[(5-chloro-1,2,3-thiadiazol-4-yl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol

The titled compound was prepared from the product of example 4, step (b), and 5-chloro-4-(chloromethyl)-1,2,3-thiadiazole, using the method of example 4, step (c).

30

MS: APCI 390 (M+H)

¹H NMR: δ (DMSO) 1.12 (d, 3H), 3.29-3.49 (m, 2H), 4.23 (m, 1H), 4.69 (t, 1H), 4.75 (q, 2H), 7.06 (d, 1H), 8.04 (bs, 2H).

35 Example 9

(2R)-2-[[2-Amino-5-[(5-isoxazolylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-propanol

The titled compound was prepared from the product of example 4, step (b), and 5-bromomethylisoxazole, using the method of example 4, step (c).

Mp 183-5C

MS: APCI 339 (M+H, 100%)

¹H NMR: δ (DMSO) 1.10 (d, 3H), 1.87 (s, 1H), 3.32-3.44 (m, 2H + H₂O), 4.17 (m, 1H), 4.49 (s, 2H), 6.36, (s, 1H), 7.06 (d, 1H), 8.03 (bs, 2H), 8.44 (s, 1H).

Example 10

2-[[2-Amino-5-[(2-methyl-4-thiazolyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1,3-propanediol

a) 6-Amino-2-[[2-methyl-4-thiazolyl)methyl]thio]-4(3H)-pyrimidinone

4-Amino-6-hydroxy-2-mercaptopyrimidine monohydrate (0.161g) and sodium hydroxide (0.08g) were stirred in dry DMF (4ml) for 20mins. 4-Chloromethyl, 2-methylthiazole hydrochloride hydrate (0.2g) was added and the mixture stirred for 3hr then poured onto water (150ml) to give a solution. The subtitled product crystallised and was collected, washed with water and dried (0.2g).

MS: ES+ 255 (M+H, 100%)

¹H NMR: δ (DMSO) 2.53 (s, 3H), 4.36 (s, 2H), 4.94 (s, 1H), 6.55 (bs, 2H), 7.44 (s, 1H), 11.46 (bs, 1H).

b) 2-Amino-5-[[2-methyl-4-thiazolyl)methyl]thio]- thiazolo[4,5-d]pyrimidin-7(6H)-one

The product from step (a) (24.3g) was stirred in dry DMF (400ml) with pyridine (13.1ml) and potassium thiocyanate (37.1g) at 0C. Bromine (4.5ml) was added over 1hr and the mixture kept at 0C for a further 2hrs. The mixture was poured onto water to give a solution which was then evaporated to low volume. Water was added to give a precipitate which was collected. The solid was dissolved in dilute hydrochloric acid and reprecipitated by the

addition of sodium bicarbonate solution. The solid was collected, washed with water and dried to afford the sub-title compound (8.7g)

MS. ES+ve 312 (M+H, 100%)

¹H NMR: δ (DMSO) 2.62 (s, 3H), 4.41 (s, 2H), 7.57 (s, 1H), 7.70 (bs, 2H), 12.37 (bs, 1H).

5

c) 7-Chloro-5-[[[(2-methyl-4-thiazolyl)methyl]thio]-thiazolo[4,5-d]pyrimidin-2-amine

The product from step (b), (8.7g), was suspended in phosphorus oxychloride (88ml) and dimethylaniline (8.8ml). The mixture was heated under reflux for 2hrs then evaporated.

The residue was stirred in hot water, cooled and the pH adjusted with sodium hydroxide solution to pH5. The solid was collected, washed with water and dried. Chromatography (SiO₂, methanol/dichloromethane as eluant) gave the sub-title compound (4.3g)

10

MS. APCI+ve 330/332 (M+H), 330 (100%).

¹H NMR: δ (DMSO) 2.63 (s, 3H), 4.44 (s, 2H), 7.36 (s, 1H), 8.96 (bs, 2H).

d) 2-[[[2-Amino-5-[[[(2-methyl-4-thiazolyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1,3-propanediol

15

The product from step (c) (0.99g) and 2-amino-1,3-propanediol (0.55g), were stirred in dry NMP (10ml) with hunigs base (1.75ml) at 100C for 20hrs. The mixture was poured onto water and evaporated. Water was added and the solid collected, washed with water and dried. A sample (0.11g) was purified by reverse phase preparative HPLC on Nova-pak[®] C18 column, using acetonitrile in 0.1% aqueous ammonium acetate gave the titled compound (0.04g)

20

Mp 158-160C

MS: APCI+ve 385 (M+H, 100%)

25

¹H NMR: δ (DMSO) 2.62 (s, 3H), 3.51 (m, 4H), 4.18 (m, 1H), 4.37 (s, 2H), 4.64 (t, 2H), 6.87, (d, 1H), 7.31 (s, 1H), 8.00 (bs, 2H).

Example 11

30

2-[[[2-Amino-5-[[[(2-methyl-4-thiazolyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-1-propanol

The titled compound was prepared from the product of example 10, step (c) and 2-amino,2-methylpropanol (0.54g) using the method of example 10, step (d).

Mp 250-252C

5 MS: APCI+ve 383 (M+H, 100%)

¹H NMR: δ (DMSO) 1.32 (s, 6H), 2.62 (s, 3H), 3.55 (d, 2H), 4.38 (s, 2H), 4.86 (t, 1H), 6.30 (s, 1H), 7.30, (s, 1H), 8.00 (bs, 2H).

10 Example 12

(2*R*)-2-[[2-Amino-5-[(2-furanylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol

15 The titled compound was prepared from the product of example 1, step (e) and furfuryl mercaptan (0.15ul) using the method of example 1, step (f) (0.024g)

Mp 145-150C

MS: APCI 338 (M+H, 100%)

20 ¹H NMR: δ (DMSO) 1.13 (d, 3H), 3.32-3.47 (m, 2H + H₂O), 4.21 (m, 1H), 4.41 (s, 2H), 4.71 (t, 1H), 6.29 (m, 1H), 6.36 (m, 1H), 7.01 (d, 1H), 7.55 (m, 1H), 8.53 (bs, 2H).

Pharmacological Data

25

Ligand Binding Assay

[¹²⁵I]IL-8 (human, recombinant) was purchased from Amersham, U.K. with a specific activity of 2,000Ci/mmol. All other chemicals were of analytical grade. High levels of hrCXCR2 were expressed in HEK 293 cells (human embryo kidney 293 cells ECACC No. 85120602) (Lee *et al.* (1992) *J. Biol. Chem.* **267** pp16283-16291). hrCXCR2 cDNA was amplified and cloned from human neutrophil mRNA. The DNA was cloned into PCRScript (Stratagene) and clones were identified using DNA. The coding sequence was sub-cloned into the eukaryotic expression vector RcCMV (Invitrogen). Plasmid DNA was prepared using Quiagen Megaprep 2500 and transfected into HEK 293 cells using Lipofectamine reagent (Gibco BRL). Cells of the highest expressing clone were harvested in phosphate-buffered

35

saline containing 0.2%(w/v) ethylenediaminetetraacetic acid (EDTA) and centrifuged (200g, 5min.). The cell pellet was resuspended in ice cold homogenisation buffer [10mM HEPES (pH 7.4), 1mM dithiothreitol, 1mM EDTA and a panel of protease inhibitors (1mM phenyl methyl sulphonyl fluoride, 2µg/ml soybean trypsin inhibitor, 3mM benzamidine, 0.5µg/ml leupeptin and 100µg/ml bacitracin)] and the cells left to swell for 10 minutes. The cell preparation was disrupted using a hand held glass mortar/PTFE pestle homogeniser and cell membranes harvested by centrifugation (45 minutes, 100,000g, 4°C). The membrane preparation was stored at -70°C in homogenisation buffer supplemented with Tyrode's salt solution (137mM NaCl, 2.7mM KCl, 0.4mM NaH₂PO₄), 0.1%(w/v) gelatin and 10%(v/v) glycerol.

All assays were performed in a 96-well MultiScreen 0.45µm filtration plates (Millipore, U.K.). Each assay contained ~50pM [¹²⁵I]IL-8 and membranes (equivalent to ~200,000 cells) in assay buffer [Tyrode's salt solution supplemented with 10mM HEPES (pH 7.4), 1.8mM CaCl₂, 1mM MgCl₂, 0.125mg/ml bacitracin and 0.1%(w/v) gelatin]. In addition, a compound of formula (I) according to the Examples was pre-dissolved in DMSO and added to reach a final concentration of 1%(v/v) DMSO. The assay was initiated with the addition of membranes and after 1.5 hours at room temperature the membranes were harvested by filtration using a Millipore MultiScreen vacuum manifold and washed twice with assay buffer (without bacitracin). The backing plate was removed from the MultiScreen plate assembly, the filters dried at room temperature, punched out and then counted on a Cobra γ-counter.

The compounds of formula (I) according to the Examples were found to have IC₅₀ values of less than (<) 10µM.

Intracellular Calcium Mobilisation Assay

Human neutrophils were prepared from EDTA-treated peripheral blood, as previously described (Baly *et al.* (1997) *Methods in Enzymology* 287 pp70-72), in storage buffer [Tyrode's salt solution (137mM NaCl, 2.7mM KCl, 0.4mM NaH₂PO₄) supplemented with 5.7mM glucose and 10mM HEPES (pH 7.4)].

The chemokine GROα (human, recombinant) was purchased from R&D Systems (Abingdon, U.K.). All other chemicals were of analytical grade. Changes in intracellular free calcium were measured fluorometrically by loading neutrophils with the calcium sensitive fluorescent dye, fluo-3, as described previously (Merritt *et al.* (1990) *Biochem. J.*


269, pp513-519). Cells were loaded for 1 hour at 37°C in loading buffer (storage buffer with 0.1%(w/v) gelatin) containing 5µM fluo-3 AM ester, washed with loading buffer and then resuspended in Tyrode's salt solution supplemented with 5.7mM glucose, 0.1%(w/v) bovine serum albumin (BSA), 1.8mM CaCl₂ and 1mM MgCl₂. The cells were pipetted
5 into black walled, clear bottom, 96 well micro plates (Costar, Boston, U.S.A.) and centrifuged (200g, 5 minutes, room temperature).

A compound of formula (I) according to the Examples was pre-dissolved in DMSO and added to a final concentration of 0.1%(v/v) DMSO. Assays were initiated by the addition
10 of an A₅₀ concentration of GROα and the transient increase in fluo-3 fluorescence (λ_{Ex} = 490nm and λ_{Em} = 520nm) monitored using a FLIPR (Fluorometric Imaging Plate Reader, Molecular Devices, Sunnyvale, U.S.A.).

The compounds of formula (I) according to the Examples were tested and found to be
15 antagonists of the CXCR2 receptor in human neutrophils.

CLAIMS

1. A compound of formula (I) or a pharmaceutically acceptable salts or solvates thereof:



5


wherein R represents a hydrogen atom, or a group $-NR^4R^5$;

R^4 and R^5 each independently represent a hydrogen atom, or a 4-piperidinyl, C_3 - C_6 cycloalkyl or C_1 - C_8 alkyl group, which latter two groups may be optionally substituted by one or more substituent groups independently selected from halogen atoms and $-NR^6R^7$, $-CONR^6R^7$, $-OR^8$, $-COOR^8$, $-NR^9COR^{10}$, $-SR^{11}$, $-SO_2R^{11}$, $-SO_2NR^6R^7$, $-NR^9SO_2R^{10}$, morpholinyl, C_1 - C_4 alkyl, C_3 - C_6 cycloalkyl, tetrahydrofuranyl, aryl and heteroaryl groups, the aryl and heteroaryl groups being optionally substituted by one or more substituents independently selected from halogen atoms and cyano, nitro, $-NR^6R^7$, $-CONR^6R^7$, $-OR^8$, $-NR^9COR^{10}$, $-SO_2NR^6R^7$, $-NR^9SO_2R^{10}$, C_1 - C_6 alkyl and trifluoromethyl groups,

15

or R^4 and R^5 together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring system, which ring system may be optionally substituted by one or more substituent groups independently selected from

20



$-NR^6R^7$, $-CONR^6R^7$, $-OR^8$, $-COOR^8$, $-NR^9COR^{10}$, and C_1 - C_6 alkyl optionally substituted by one or more substituents independently selected from halogen atoms and $-NR^{11}R^{12}$ and $-OR^8$ groups,

R^1 represents a C_1 - C_8 alkyl group optionally containing one or more atoms independently selected from O, NR^6 or S which terminates in a heteroaryl group, the latter group may be optionally substituted by one or more substituent groups independently selected from halogen atoms, $-NR^6R^7$, $-CONR^6R^7$, $-OR^8$, $-COOR^8$, $-NR^9COR^{10}$, $-SR^{11}$, $-SO_2R^{11}$, $-SO_2NR^6R^7$, $-NR^9SO_2R^{10}$, C_1 - C_6 alkyl, trifluoromethyl, or an aryl or heteroaryl group each

25

of which can be optionally substituted by one or more substituents independently selected from halogen atoms, cyano, nitro, $-NR^6R^7$, $-CONR^6R^7$, $-OR^8$, $-COOR^8$, $-NR^9COR^{10}$, $-SR^{11}$, $-SO_2R^{11}$, $-SO_2NR^6R^7$, $-NR^9SO_2R^{10}$, C_1 - C_6 alkyl or trifluoromethyl groups.

- 5 R^2 and R^3 each independently represent a hydrogen atom, or a C_3 - C_7 carbocyclic, C_1 - C_8 alkyl, C_2 - C_6 alkenyl or C_2 - C_6 alkynyl group, the latter four groups may be optionally substituted by one or more substituent groups independently selected from:
halogen atoms, $-NR^6R^7$, $-CONR^6R^7$, $-OR^8$, $-COOR^8$, $-NR^9COR^{10}$, $-SR^{11}$, $-SO_2R^{11}$, $-SO_2NR^6R^7$, $-NR^9SO_2R^{10}$
- 10 or
a 3-8 membered ring optionally containing one or more atoms selected from O, S, NR^9 and itself optionally substituted by C_{1-3} -alkyl, halogen,

- R^8 represents hydrogen, C_1 - C_6 alkyl or a phenyl group the latter two of which may be
15 optionally substituted by one or more substituent groups independently selected from halogen atoms, phenyl, $-OR^{14}$ and $-NR^{15}R^{16}$, $-CONR^{15}R^{16}$, $-NR^{15}COR^{16}$, $-SO_2NR^{15}R^{16}$, $NR^{15}SO_2R^{16}$

- R^6 and R^7 independently represent a hydrogen atom or a C_1 - C_6 alkyl or phenyl group the
20 latter two of which may be optionally substituted by one or more substituent groups independently selected from halogen atoms, phenyl, $-OR^{14}$ and $-NR^{15}R^{16}$, $-CONR^{15}R^{16}$, $-NR^{15}COR^{16}$, $-SO_2NR^{15}R^{16}$, $NR^{15}SO_2R^{16}$
- or
 R^6 and R^7 together with the nitrogen atom to which they are attached form a 4- to
25 7-membered saturated heterocyclic ring system optionally comprising a further heteroatom selected from oxygen and nitrogen atoms, which ring system may be optionally substituted by one or more substituent groups independently selected from phenyl, $-OR^{14}$, $-COOR^{14}$, $-NR^{15}R^{16}$, $-CONR^{15}R^{16}$, $-NR^{15}COR^{16}$, $-SO_2NR^{15}R^{16}$, $NR^{15}SO_2R^{16}$ or C_1 - C_6 alkyl, itself optionally substituted by one or more substituents independently selected from halogen
30 atoms and $-NR^{15}R^{16}$ and $-OR^{17}$ groups,

R^{11} represents a hydrogen atom or a C_1 - C_6 , or phenyl group, each of which may be optionally substituted by one or more substituent groups independently selected from halogen atoms, phenyl, $-OR^{17}$ and $-NR^{15}R^{16}$, and

R^9 , R^{10} , R^{12} , R^{13} , R^{14} , R^{15} , R^{16} , and R^{17} independently represent a hydrogen atom or a C_1 - C_6 , alkyl, or a phenyl group.

2. A compound according to claim 1, wherein R represents a group $-NR^4R^5$.

3. A compound according to claim 1 or claim 2, wherein R^4 and R^5 each represent a hydrogen atom.

4. A compound according to any one of claims 1 to 3, wherein R^1 represents a C_1 alkyl group substituted by an optionally substituted five-membered heterocycle.

5. A compound according to any one of the preceding claims, wherein one of R^2 and R^3 is hydrogen and the other is C_1 - C_8 alkyl substituted by hydroxy and one or more methyl or ethyl groups.

6. A compound according to claim 1 being selected from:

2-[[2-Amino-5-[(1*H*-benzimidazol-2-yl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol

2-[[2-Amino-5-[(2-furanylmethyl)thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol

2-[[2-Amino-5-[[1-(2-thienyl)ethyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-2-methyl-1-propanol

(2*R*)- 2-[[2-amino-5-[[2-methyl-4-thiazolyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol

(2*R*)- 2-[[2-Amino-5-[[3,5-dimethyl-4-isoxazolyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol

(2*R*)- 2-[[2-Amino-5-[[5-methyl-2-furanyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol.

N-[4-[[[2-Amino-7-[[1*R*]-2-hydroxy-1-methylethyl]amino]thiazolo[4,5-*d*]pyrimidin-5-yl]thio]methyl]-2-thiazolyl]-acetamide,

(2*R*)-2-[[2-Amino-5-[[5-chloro-1,2,3-thiadiazol-4-yl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol

(2*R*)-2-[[2-Amino-5-[(5-isoxazolyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1-propanol

2-[[2-Amino-5-[[2-methyl-4-thiazolyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-1,3-propanediol

2-[[2-Amino-5-[(2-methyl-4-thiazolyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-
2-methyl-1-propanol


(2R)-2-[[2-Amino-5-[(2-furanylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-
propanol

5 and their pharmaceutically acceptable salts and solvates.

7. A process for the preparation of a compound of formula (I) as defined in claim 1
which comprises:

a) treatment of a compound of formula (II):


10



where R, R¹, R² and R³ are as defined in formula (I) or are protected derivatives thereof
with a thiol R¹SH in the presence of a base, or

15

(b) treatment of a compound of formula (III):



20 where R, R² and R³ are as defined in formula (I) or are protected derivatives thereof with a
compound of formula R¹X where R¹ is as defined in formula (I) and X is a leaving group,
and optionally after (a) or (b):

- removing any protecting groups;
- forming a pharmaceutically acceptable salt or solvate.

25

8. An intermediate compound of formula (II) as defined in claim 7.

9. A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 6 in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

5

10. A process for the preparation of a pharmaceutical composition as claimed in claim 9 which comprises mixing a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 6 with a pharmaceutically acceptable adjuvant, diluent or carrier.

10

11. A compound of formula (I), or a pharmaceutically-acceptable salt or solvate thereof, as claimed in any one of claims 1 to 6 for use in therapy.

12. Use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 6 in the manufacture of a medicament for use in therapy.

13. A method of treating a chemokine mediated disease wherein the chemokine binds to one or more chemokine receptors, which comprises administering to a patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 6.

14. A method according to claim 13 in which the chemokine receptor belongs to the CXC chemokine receptor subfamily.

25

15. A method according to claim 13 or 14 in which the chemokine receptor is the CXCR2 receptor.

16. A method of treating an inflammatory disease in a patient suffering from, or at risk of, said disease, which comprises administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 6.

17. A method according to claim 16, wherein the disease is psoriasis, a disease in which angiogenesis is associated with raised CXCR2 chemokine levels, or COPD.

35

18. A method according to claim 16, wherein the disease is psoriasis.
19. A compound of formula (II) as defined in claim 7.
- 5 20. A compound of formula (III) as defined in claim 7.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 01/00247

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: C07D 513/04, A61K 31/519, A61P 11/00, A61P 17/06, A61P 29/00
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: C07D, A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E,X	WO 0125242 A1 (ASTRAZENECA UK LIMITED), 12 April 2001 (12.04.01), see examples and claims --	1-5,7-8, 19-20
P,X	WO 0009511 A1 (ASTRA PHARMACEUTICALS LTD.), 24 February 2000 (24.02.00), see whole document --	1-20
X	STN International, file CAPLUS, CAPLUS accession no. 1996:243961, document no. 125:10744, Gewald. K.et al: "New synthesis of substituted 4-aminoquinazolines and their hetero analogs", J. Prakt. Chem/Chem.-Ztg. (1996), 338(3,), 206-13 --	1,2,7



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"I" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

18 June 2001

Date of mailing of the international search report

25-06-2001

Name and mailing address of the ISA

Swedish Patent Office

Box 5055, S-102 42 STOCKHOLM

Facsimile No. +46 8 666 02 86

Authorized officer

Nebil Gecer/BS

Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 01/00247

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0778277 A1 (PFIZER INC.), 11 June 1997 (11.06.97), see claims 1 and 18 --	1-20
X	WO 9808847 A1 (PFIZER INC.), 5 March 1998 (05.03.98), see claims 1 and 16-19 --	1-20
X	WO 9951608 A1 (DU PONT PHARMACEUTICALS COMPANY), 14 October 1999 (14.10.99), see claims 1 and 5 --	1-20
A	WO 9825617 A1 (MERCK & CO. INC.), 18 June 1998 (18.06.98), see claim 8 -- -----	1-20

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE01/00247

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: **13-18**
because they relate to subject matter not required to be searched by this Authority, namely:
see next sheet
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE01/00247

Claims 13-18 relate to methods of treatment of the human or animal body by surgery or by therapy/ diagnostic methods practised on the human or animal body/Rule 39.1.(iv). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compounds/compositions.

INTERNATIONAL SEARCH REPORT
Information on patent family members

28/05/01

International application No.
PCT/SE 01/00247

Patent document cited in search report			Publication date	Patent family member(s)		Publication date
WO	0125242	A1	12/04/01	SE	9903544 D	00/00/00
WO	0009511	A1	24/02/00	AU	5662599 A	06/03/00
				SE	9802729 D	00/00/00
EP	0778277	A1	11/06/97	CA	2192289 A	09/06/97
				JP	9188682 A	22/07/97
				JP	2000109431 A	18/04/00
WO	9808847	A1	05/03/98	AP	762 A	13/09/99
				AP	9701077 D	00/00/00
				AU	3456197 A	19/03/98
				BG	103189 A	30/09/99
				BR	9711970 A	24/08/99
				CN	1227554 A	01/09/99
				CZ	9900681 A	17/11/99
				EP	0923582 A	23/06/99
				HR	970454 A	31/08/98
				HU	9903965 A	28/03/00
				IL	127566 D	00/00/00
				JP	2000502723 T	07/03/00
				NO	990927 A	26/02/99
				PL	332040 A	16/08/99
				SK	23399 A	14/08/00
				TR	9900389 T	00/00/00
				ZA	9707687 A	01/03/99
WO	9951608	A1	14/10/99	AU	3213699 A	25/10/99
				EP	0959418 A	24/11/99
				EP	1068212 A	17/01/01
				US	6107294 A	22/08/00
WO	9825617	A1	18/06/98	AU	5522498 A	03/07/98